Resultats globals: 1 registres trobats en 0.02 segons.
Articles, 1 registres trobats
Articles 1 registres trobats  
1.
12 p, 1.3 MB Cediranib in patients with alveolar soft-part sarcoma (CASPS) : a double-blind, placebo-controlled, randomised, phase 2 trial / Judson, Ian (The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust) ; Morden, James P. (The Institute of Cancer Research) ; Kilburn, Lucy (The Institute of Cancer Research) ; Leahy, Michael (The Christie NHS Foundation Trust) ; Benson, Charlotte (The Royal Marsden NHS Foundation Trust) ; Bhadri, Vivek (Chris O'Brien Lifehouse) ; Campbell-Hewson, Quentin (Newcastle upon Tyne Hospitals NHS Foundation Trust) ; Cubedo, Ricardo (Hospital Universitario Puerta de Hierro Majadahonda (Madrid)) ; Dangoor, Adam (University Hospitals Bristol NHS Foundation Trust) ; Fox, Lisa (The Institute of Cancer Research) ; Hennig, Ivo (Nottingham University Hospitals NHS Trust (Regne Unit)) ; Jarman, Katy (The Institute of Cancer Research) ; Joubert, Warren (Princess Alexandra Hospital) ; Kernaghan, Sarah (The Institute of Cancer Research) ; López Pousa, Antonio (Institut d'Investigació Biomèdica Sant Pau) ; McNeil, Catriona (Chris O'Brien Lifehouse) ; Seddon, Beatrice (University College London Hospitals NHS Foundation Trust) ; Snowdon, Claire (The Institute of Cancer Research) ; Tattersall, Martin (Chris O'Brien Lifehouse) ; Toms, Christy (The Institute of Cancer Research) ; Martinez Trufero, Javier (Hospital Universitario Miguel Servet (Saragossa)) ; Bliss, Judith M. (The Institute of Cancer Research) ; Universitat Autònoma de Barcelona
Alveolar soft-part sarcoma (ASPS) is a rare soft-tissue sarcoma that is unresponsive to chemotherapy. Cediranib, a tyrosine-kinase inhibitor, has shown substantial activity in ASPS in non-randomised studies. [...]
2019 - 10.1016/S1470-2045(19)30215-3
The Lancet. Oncology, Vol. 20 Núm. 7 (july 2019) , p. 1023-1034  

Vegeu també: autors amb noms similars
Us interessa rebre alertes sobre nous resultats d'aquesta cerca?
Definiu una alerta personal via correu electrònic o subscribiu-vos al canal RSS.